##### 



EXHIBIT 10.2




---



##### 



EXECUTION
COPY
 IN THE UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF TENNESSEE
GREENEVILLE DIVISION
 IN RE: KING PHARMACEUTICALS,
    
    No. 2:03-CV-77INC. SECURITIES LITIGATIONDistrict Judge Thomas W. PhillipsTHIS DOCUMENT RELATES TO:All Actions
    
    Magistrate Judge Dennis H. Inman
   STIPULATION OF SETTLEMENT
 
 Attorneys for Lead Plaintiffs and Lead Counsel for the Class
 
 Attorneys for the Jones Merger Lead Plaintiff and Lead Counsel for the Jones Merger Subclass
 
 Attorneys for the King Defendants
 
 Attorneys for the Underwriter Defendants




---



##### 



TABLE OF CONTENTS
 I. THE LITIGATION AND RELATED PROCEEDINGS
    
    
    1II.
    
    DEFENDANTS DENIALS OF WRONGDOING AND LIABILITY
    
    
    3III.
    
    CLAIMS OF THE PLAINTIFFS AND BENEFITS OF SETTLEMENT
    
    
    4IV.
    
    TERMS OF STIPULATION AND AGREEMENT OF SETTLEMENT
    
    
    41.
    
    
    Definitions
    
    
    52.
    
    
    The Settlement
    
    
    11a.    The Settlement Fund
    
    
    11b.    The Escrow Account
    
    
    11c.    Taxes
    
    
    12d.    Termination
    
    
    143.
    
    
    Releases
    
    
    154.
    
    
    Notice Order And Settlement Hearing
    
    
    155.
    
    
    Administration and Calculation of Claims, Final Awards and Supervision and Distribution of the Settlement Fund
    
    
    166.
    
    
    Plaintiffs Counsels Attorneys Fees And Reimbursement of Expenses
    
    
    187.
    
    
    Conditions Of Settlement, Effect of Disapproval, Cancellation or Termination
    
    
    208.
    
    
    Miscellaneous Provisions
    
    
    21




---



##### 



INDEX TO EXHIBITS
 [Proposed] Order Preliminarily Approving Settlement and Providing for Notice
    
    Exhibit ANotice of Pendency of Class Action and of Proposed Class Action Settlement
    
    Exhibit BSummary Notice of Pendency of Class Action and Proposed Class Action Settlement
    
    Exhibit CProof of Claim
    
    Exhibit D[Proposed] Judgment
    
    Exhibit E
 iii




---



##### 



EXECUTION COPY
  I. THE LITIGATION AND RELATED PROCEEDINGS
 In re King Pharmaceuticals, Inc. Securities Litigation




---



##### 



2




---



##### 



II. DEFENDANTS DENIALS OF WRONGDOING AND LIABILITY
 inter alia
 3




---



##### 



III. CLAIMS OF THE PLAINTIFFS AND BENEFITS OF SETTLEMENT
  IV. TERMS OF STIPULATION AND AGREEMENT OF SETTLEMENT
  4




---



##### 



1. Definitions
       5




---



##### 



6




---



##### 



Exhibit E
       7




---



##### 



8




---



##### 



9




---



##### 





10




---



##### 



2. The Settlement
 a. The Settlement Fund
     b. The Escrow Account
  11




---



##### 



custodia legis
   c. Taxes
  12




---



##### 



13




---



##### 



d. Termination
 application(s)
 14




---



##### 



3.
Releases
   4. Notice Order And Settlement Hearing
 Exhibit A inter alia Exhibit B Exhibit C
  15




---



##### 



5.
    
    Administration and Calculation of Claims, Final Awards and Supervision and Distribution of
the Settlement Fund
  Exhibit D
  16




---



##### 



(a)
    
    to pay all the costs and expenses reasonably and actually incurred in connection
with providing notice, locating Class Members, soliciting Class claims, assisting with
the filing of claims, administering and distributing the Settlement Fund to Authorized
Claimants, processing Proof of Claim and Release forms, and paying Escrow Fees;(b)
    
    to pay Taxes and Tax Expenses;(c)
    
    to pay the Fee and Expense Award, if and to the extent allowed by the Court; and(d)
    
    to distribute the balance of the Settlement Fund (the Net Settlement Fund) to
Authorized Claimants as allowed by the Plan of Allocation or such further order(s) of
the Court as may be necessary or as circumstances may require.
    17




---



##### 



6. Plaintiffs Counsels Attorneys Fees And Reimbursement of Expenses
  18




---



##### 



plus
 19




---



##### 



7. Conditions Of Settlement, Effect of Disapproval, Cancellation or Termination
   20




---



##### 



nunc pro tunc
  8. Miscellaneous Provisions
  21




---



##### 



22




---



##### 



res judicata,
   23




---



##### 



24




---



##### 



Dated: 7-31-06
    
    /s/ Robert S. Gans

Robert GansBERNSTEIN LITOWITZ BERGER &     GROSSMANN LLP12481 High Bluff Drive, Suite 300San Diego, CA 92130(858) 793-0070Jeffrey N. LeibellJohn C. BrowneBERNSTEIN LITOWITZ BERGER &     GROSSMANN LLP1285 Avenue of the AmericasNew York, NY 10019(212) 554-1400R. Garry ChaffinLinda BurnsedCHERNAU, CHAFFIN & BURNSED PLLCSunTrust Center, Suite 1750424 Church StreetNashville, TN 37219(615) 244-5480Attorneys for Lead Plaintiffs
andLead Counsel for the Class
 25




---



##### 



Dated: July 31, 2006
    
    /s/ Joseph H. Weiss

Joseph H. WeissMark D. SmilowIlya NuzovWEISS & LURIE551 Fifth AvenueNew York, NY 10176(212) 682-3025Dated: July 31, 2006
    
    /s/ Stephen J. Rodd w/permission MDS

Stephen J. RoddArthur N. AbbeyMeagan ZapotockyABBEY SPANIER RODD ABRAMS &    
PARADIS, LLP212 East 39th StreetNew York, NY 10016(212) 889-3700Attorneys for the Jones Merger Lead Plaintiff and

 Lead Counsel for the Jones Merger
Subclass
 26




---



##### 



Dated: 7-31-2006
    
    /s/ John C. Millian

John C. MillianDaniel A. CantuJill S. HendersonGIBSON, DUNN & CRUTCHER LLP1050 Connecticut Avenue, N.W.Washington, DC 20036(202) 955-8500Andrew L. Colocotronis (BPR No. 017052)Ashley M. Lowe (BPR No. 20867)BAKER, DONELSON, BEARMAN, CALDWELL
& BERKOWITZ, P.C.900 S. Gay Street, Suite 2200Knoxville, TN 37902(865) 549-7000Attorneys for the King DefendantsDated: 7/31/06
    
    /s/ Lawrence J. Portnoy

Lawrence J. PortnoyLindsay H. TomensonDAVIS POLK & WARDWELL450 Lexington AvenueNew York, NY 10017
 (212)450-4000Jimmie C. MillerHUNTER SMITH & DAVIS LLP1212 North Eastman RoadP.O. Box 3740Kingsport, TN 37664(423) 378-8852Attorneys for the Underwriter Defendants
 27




---



##### 



EXHIBIT Ato Stipulationof Settlement
 IN THE UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF TENNESSEE
GREENEVILLE DIVISION
 IN RE: KING PHARMACEUTICALS,
INC. SECURITIES LITIGATION
    
    No. 2:03-CV-77THIS DOCUMENT RELATES TO:
All Actions
    
    District Judge Thomas W. PhillipsMagistrate Judge Dennis H. Inman
 [PROPOSED] ORDER PRELIMINARILY APPROVING
SETTLEMENT AND PROVIDING FOR NOTICE
 In re King
Pharmaceuticals, Inc. Securities Litigation,




---



##### 



A-2




---



##### 



The Wall Street Journal.
  A-3




---



##### 



A-4




---



##### 



A-5




---



##### 



custodia legis,
  A-6




---



##### 



A-7




---



##### 



THE HONORABLE THOMAS W. PHILLIPS UNITED STATES
DISTRICT JUDGE
 A-8




---



##### 



EXHIBIT Bto Stipulationof Settlement
 IN THE UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF TENNESSEE
GREENEVILLE DIVISION
 IN RE: KING PHARMACEUTICALS,
INC. SECURITIES LITIGATION
    
    No. 2:03-CV-77THIS DOCUMENT RELATES TO:
All Actions
    
    District Judge Thomas W. PhillipsMagistrate Judge Dennis H. Inman
 NOTICE OF PENDENCY OF CLASS ACTION AND
PROPOSED CLASS ACTION SETTLEMENT
 TO:
    
    All persons or entities who purchased King Pharmaceuticals, Inc.
(King) common stock between February 16, 1999, and March 10, 2003,
inclusive (the Class Period), including all persons or entities who
acquired shares of King common stock pursuant to any offering
completed during the Class Period, and who were damaged thereby
(Class Members).A federal court authorized this Notice. This is not a solicitation
from a lawyer.Please read this Notice carefully and in its entirety.
Your rights will be affected by proceedings in this litigation whether
you act or do not act.If you are a Class Member, please be advised that your rights may be
affected by a Class Action lawsuit pending in the United States
District Court
for the Eastern District of Tennessee, and you may be entitled to share in the proceeds of
the Settlement described in this Notice. To claim your share of the Settlement Fund, you
must submit a valid Proof of Claim and Release form postmarked on or before, 2006.
If you are a Class Member and do not submit a timely request for exclusion, you will be
bound by the release whether or not you submit a claim.




---



##### 



YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT
 Submit a Proof of Claim and Release Form
no later than, 2006.
    
    This is the only way to receive a share of the
Settlement Fund.Request exclusion from the Class in
writing no later than, 2006.
    
    Receive no payment from the Settlement
Fund. This is the only option that allows you
to ever be part of any other lawsuit against the
Defendants about the Settled Claims.Object to the Settlement in writing no later
than, 2006.
    
    Write to the court about why you do not like
the Settlement, and ask the Court not to
approve it.Go to the Settlement Hearing to be held on
, 2006, at  a.m..
Do nothing.
    
    Ask permission to speak to the Court about the
settlement.
If you do nothing, you will receive no
payment and will give up your rights.
 These rights and options, and the deadlines to exercise them, are explained in this Notice.
 The Court in charge of this case still has to decide whether to approve the Settlement. Payments
will be made if the Court approves the Settlement and after any appeals are resolved.
 SUMMARY OF SETTLEMENT AND RELATED MATTERS
   B-2




---



##### 



Class Recovery
   Reasons for the Settlement
    B-3




---



##### 



Statement of Attorneys Fees and Costs Sought
  Further Information
  Lead Counsel:
    
    Jones Subclass Lead Counsel:
    
    Claims Administrator:Robert S. Gans, Esq.
    
    Joseph H. Weiss, Esq.BERNSTEIN LITOWITZ
    
    Mark D. Smilow, Esq.
    
    In re King Pharmaceuticals,BERGER & GROSSMANN LLP
    
    WEISS & LURIE
    
    Inc. Securities Litigation12481 High Bluff Drive,
    
    551 Fifth Avenue
    
    c/o A.B. Data, Ltd.Suite 300
    
    New York, NY 10176
    
    4057 North Wilson DriveSan Diego, CA 92130
    
    (212) 682-3025
    
    Milwaukee, WI 53211(858) 793-0070
    
    
    
    (866) 561-6065
 Please do not call any representative of King or the Court.
 [END OF COVER PAGE]
 B-4




---



##### 



WHAT THIS NOTICE CONTAINS
 PageBASIC INFORMATION
    
    
    61. Why Did I Get This Notice Package?
    
    
    62. What Is This Lawsuit About?
    
    
    73. Why Is There A Settlement With Defendants?
    
    
    7WHO IS IN THE SETTLEMENT
    
    
    74. How Do I Know If I Am Part of the Settlement?
    
    
    75. Who Is Included In the Class? Who Is Excluded?
    
    
    76. Im Still Not Sure If Im Included
    
    
    7THE SETTLEMENT BENEFITSWHAT YOU GET
    
    
    77. What Does the Settlement Provide?
    
    
    78. How Much Will My Payment Be?
    
    
    8HOW YOU GET A PAYMENTSUBMITTING A CLAIM FORM
    
    
    109. How Will I Get A Payment?
    
    
    1010. When Will I Get My Payment?
    
    
    10THE LAWYERS REPRESENTING YOU
    
    
    1011. Do I Have A Lawyer In This Case?
    
    
    1012. How Will the Lawyers Be Paid?
    
    
    10OBJECTING TO THE SETTLEMENT
    
    
    1113. How Do I Tell the Court That I Dont Like the Settlement?
    
    
    11EXCLUDING YOURSELF FROM THE SETTLEMENT
    
    
    1214. Whats the Difference Between Objecting and Excluding?
    
    
    12THE COURTS FAIRNESS HEARING
    
    
    1215. When and Where Will the Court Decide Whether to Approve the Settlement?
    
    
    1216. Do I Have to Come to the Hearing?
    
    
    1317. May I Speak at the Hearing?
    
    
    13IF YOU DO NOTHING
    
    
    1318. What Happens If I Do Nothing At All?
    
    
    13GETTING MORE INFORMATION
    
    
    1319. Are There More Details About the Settlement?
    
    
    1320. How Do I Get More Information?
    
    
    13SPECIAL NOTICE TO NOMINEES
    
    
    14
 B-5




---



##### 



BASIC INFORMATION
 1. Why Did I Get This Notice Package?
  In re King Pharmaceuticals,
Inc. Securities Litigation,
  2. What Is This Lawsuit About?
     B-6




---



##### 



3. Why Is There A Settlement With Defendants?
  WHO IS IN THE SETTLEMENT
 4. How Do I Know If I Am Part of the Settlement?
 and except
 5. Who Is Included In the Class? Who Is Excluded?
 and were damaged thereby.
  6. Im Still Not Sure If Im Included.
 kingsecuritieslitigation@abdatalawserve.com http://www.abdatalawserve.com
 THE SETTLEMENT BENEFITSWHAT YOU GET
 7. What Does the Settlement Provide?
  B-7




---



##### 



8. How Much Will My Payment Be?
   
   Open Market Purchases.
 Shares Acquired Pursuant to the Registration Statement Filed in Connection with the Jones Merger
or the Registration Statement Filed in Connection with the Public Offering of King Common Stock
that was Completed on November 1, 2001.
   B-8




---



##### 



B-9




---



##### 



HOW YOU GET A PAYMENTSUBMITTING A CLAIM FORM
 9. How Will I Get A Payment?
 http://www.abdatalawserve.com
 10. When Will I Get My Payment?
 
 THE LAWYERS REPRESENTING YOU
 11. Do I Have A Lawyer In This Case?
  B-10




---



##### 



12. How Will the Lawyers Be Paid?
   OBJECTING TO THE SETTLEMENT
  13. How Do I Tell the Court That I Dont Like the Settlement?
  In re: King
Pharmaceuticals, Inc. Securities Litigation
 Court:
    
    Lead Counsel:
    
    Jones Subclass LeadCounsel:Clerk of CourtUnited States District Court
    
    Robert S. Gans, Esq.
    
    Joseph H. Weiss, Esq.for the Eastern District of
    
    BERNSTEIN LITOWITZ
    
    Mark D. Smilow, Esq.
 B-11




---



##### 



Tennessee
    
    BERGER & GROSSMANN LLP
    
    WEISS & LURIE800 Market Street
    
    12481 High Bluff Drive,
    
    551 Fifth AvenueKnoxville, TN 37902
    
    Suite 300
    
    New York, NY 10176San Diego, CA 92130
    
    (212) 682-3025(858) 793-0070King Defendants Counsel:
    
    Underwriter Defendants
Counsel:John C. Millian, Esq.Daniel A. Cantu, Esq.
    
    Lawrence J. Portnoy, Esq.GIBSON, DUNN &
    
    Lindsay H. Tomenson, Esq.CRUTCHER LLP
    
    DAVIS POLK & WARDWELL1050 Connecticut Avenue,
    
    450 Lexington AvenueN.W.
    
    New York, NY 10017Washington, D.C. 20036
 EXCLUDING YOURSELF FROM THE SETTLEMENT
  In re: King Pharmaceuticals, Inc.
Securities Litigation
 
 You must submit a written request for exclusion.
 14. Whats the Difference Between Objecting And Excluding?
  B-12




---



##### 



THE COURTS FAIRNESS HEARING
  15. When And Where Will The Court Decide Whether To Approve The Settlement?
  16. Do I Have to Come to the Hearing?
  17. May I Speak At the Hearing?
 In re: King Pharmaceuticals, Inc.
Securities Litigation
 IF YOU DO NOTHING
 18. What Happens If I Do Nothing At All?
  B-13




---



##### 



GETTING MORE INFORMATION
 19. Are There More Details About the Settlement?
  20. How Do I Get More Information?
 http://www.abdatalawserve.com Do not telephone the Court regarding
this Notice.
 SPECIAL NOTICE TO NOMINEES
 WITHIN SEVEN (7) DAYS OF YOUR
RECEIPT OF THIS NOTICE
  DATED: ___, 2006.BY ORDER OF THE COURT:UNITED STATES DISTRICT JUDGE
 B-14




---



##### 



EXHIBIT C
to Stipulation
of Settlement
 IN THE UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF TENNESSEE
GREENEVILLE DIVISION
 IN RE: KING PHARMACEUTICALS,
    
    No. 2:03-CV-77INC. SECURITIES LITIGATIONDistrict Judge Thomas W. PhillipsTHIS DOCUMENT RELATES TO:All Actions
    
    Magistrate Judge Dennis H. Inman
 SUMMARY NOTICE OF PENDENCY OF CLASS ACTION AND OF
PROPOSED CLASS ACTION SETTLEMENT
 TO:
    
    All persons or entities who purchased King Pharmaceuticals, Inc. (King) Common Stock
during the period from February 16, 1999 to March 10, 2003, inclusive, including persons who
acquired shares of King common stock pursuant to any offering completed during the Class
Period, and who were damaged thereby (Class Members).
 YOU ARE HEREBY NOTIFIED
 YOUR RIGHTS WILL BE AFFECTED BY PROCEEDINGS IN THIS LITIGATION WHETHER YOU ACT OR DO NOT
ACT. IF YOU ARE A CLASS MEMBER YOU MAY BE ENTITLED TO SHARE IN THE PROCEEDS OF THE
SETTLEMENT FUND.




---



##### 



www.blbglaw.com.
 YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT:
 
    
    If you are a Class Member, in order to share in the distribution of the settlement fund,
you must submit a Claim Form establishing that you are entitled to recovery to the Claims
Administrator (at the address above) by no later than ___, 2006. [120 days after
Notice Date] If you are a Class Member and do not take timely action to exclude yourself from
the settlement, you will be bound by any judgment rendered in the litigation whether or not
you submit a claim.
    
    To exclude yourself from the Class, you must file a request for exclusion on or before
___, 2006, in the manner prescribed in the Notice. All Class Members who do not request
exclusion from the Class will be bound by any judgment entered in the Litigation.
    
    Any objection to the proposed Settlement, plan of allocation and/or application for
attorneys fees and expenses must be filed with the Court on or before ___, 2006, and
delivered to counsel for the parties in the manner and form set forth in the Notice.
 PLEASE DO NOT CONTACT THE COURT OR THE CLERKS OFFICE
REGARDING THIS NOTICE.Inquires, other than requests for the Notice and Claim Form, may be
made to Lead Counsel and/or Jones Subclass Lead Counsel:
 Lead Counsel:
    
    Jones Subclass Lead Counsel:Robert S. Gans, Esq.
    
    Joseph H. Weiss, Esq.BERNSTEIN LITOWITZ BERGER &
    
    Mark D. Smilow, Esq.GROSSMANN LLP
    
    WEISS & LURIE12481 High Bluff Drive,
    
    551 Fifth AvenueSuite 300
    
    New York, NY 10176San Diego, CA 92130
    
    (212) 682-3025(858) 793-0070
 D-2




---



##### 



EXHIBIT D
to Stipulation
of Settlement


IN THE UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF TENNESSEE
GREENEVILLE DIVISION


IN RE: KING PHARMACEUTICALS,
    
    No. 2:03-CV-77INC. SECURITIES LITIGATIONDistrict Judge Thomas W. PhillipsTHIS DOCUMENT RELATES TO:All ActionsMagistrate Judge Dennis H. Inman


PROOF OF CLAIM


Must be Postmarked  No Later Than   2006


IN RE KING PHARMACEUTICALS, INC. SECURITIES LITIGATION
c/o A.B. Data, Ltd.
P.O. Box 170500
Milwaukee, WI 53217-8041 (800) XXX-XXXX


PROOF OF CLAIM AND RELEASE


Identity of Claimant:











Daytime Telephone Number:
    
    
    (
    
    
    )
    
    
    -




Evening Telephone Number:
    
    

    (
    
    
    )
    
    
    -




REQUIRED INFORMATION OR CORRECTIONS
 ORif there is no preprinted data to the left, YOU
MUSTprovide your name and address here :
 Name:Address:City:State:Zip Code:


Claimant is:


?
    
    Individual
    
    ?
    
    Joint Owners?
    
    Estate
    
    ?
    
    Corporation?
    
    Trust
    
    ?
    
    Partnership?
    
    Other
    
    ?
    
    IRA, Keogh or the Retirement Plan(Specify)







---



##### 



Name
of Beneficial Owner, if different than Claimant:   ?
 GENERAL INSTRUCTIONS
     You are required to submit genuine and sufficient documentation for all your transactions in
King common stock during the Class Period, i.e. , between February 16, 1999 through and including
March 10, 2003. In addition, you are required to submit genuine and sufficient documentation to
show your holdings in King common stock as the opening of the Class Period and as of the close of
the Class Period.
  NOT
  D-2




---



##### 



SCHEDULE OF TRANSACTIONS IN KING COMMON STOCK
 Be sure to include your name and
Social Security number or Tax ID number on any additional sheets.
 SECTION B: BEGINNING HOLDINGS:Please state the number of shares of King common stock that you
owned as of the opening of trading on February 16, 1999.If you did not own any shares of King common stock as of the opening of
trading on February 16, 1999 please check
here.SECTION C: JONES MERGER:Please state the number of shares of King common stock that you acquired
in connection with the August 2000 merger of Jones Pharmaceuticals, Inc. and King.If you did not acquire any shares of King in connection with the Jones merger,
please check here.SECTION D: NOVEMBER 2001 OFFERING:Please state the number of shares of King common Stock that you
acquired in connection with the public offering of 16 million shares of King common stock that was
completed in November 2001.If you did not acquire any shares of King in connection with the November 2001
Offering, please check here.
 D-3




---



##### 



SECTION P PURCHASES:
  TotalDate(s) of Purchase
    
    Number
    
    
    
    Purchase Price(List Chronologically)
    
    Of Shares
    
    Purchase Price
    
    (excluding taxes,(Month/Day/Year)
    
    Purchased
    
    Per Share
    
    commissions, etc.)___/___/___
    
    _______
    
    $_______
    
    $__________/___/___
    
    _______
    
    $_______
    
    $__________/___/___
    
    _______
    
    $_______
    
    $__________/___/___
    
    _______
    
    $_______
    
    $_______
 SECTION S: SALES:
  TotalDate(s) of Sale
    
    Number
    
    
    
    Sale Price(List Chronologically)
    
    Of Shares
    
    Sale Price
    
    (excluding taxes,(Month/Day/Year)
    
    Sold
    
    Per Share
    
    commissions, etc.)___/___/___
    
    _______
    
    $_______
    
    $__________/___/___
    
    _______
    
    $_______
    
    $__________/___/___
    
    _______
    
    $_______
    
    $_______
 SECTION U: UNSOLD HOLDINGS.Please state the number of shares of King common stock that you
held as of the close of trading on March 10, 2003.If you did not own any shares of King common stock as of the close of
trading on March 10, 2003, please check here.
 VERIFICATION AND ACKNOWLEDGEMENT
  D-4




---



##### 



In re King
Pharmaceuticals, Inc. Securities Litigation
        D-5




---



##### 



Date
    
    Signature of ClaimantDate
    
    Signature of Joint Claimant, if any
  Date
    
    Signature of person completing 
form
    
    Capacity of person signing
 SUBSTITUTE
FORM W-9
    Date
    
    Signature of OwnerDate
    
    Signature of Joint Owner (if any)
  Name of Person Signing

    Capacity of
Person Signing
 D-6




---



##### 



ACCURATE PROCESSING TAKES A
SIGNIFICANT AMOUNT OF TIME.
THANK YOU FOR YOUR PATIENCE.
 REMINDER CHECKLIST
 1.
    
    Please sign both the Claim Form on page 4 and the Substitute Form W-9 on page
4.2.
    
    If this Claim is made on behalf of joint claimants, then both must sign.3.
    
    Please, remember to attach supporting documents.4.
    
    DO NOT SEND ORIGINALS OF ANY SUPPORTING DOCUMENTS.5.
    
    Keep a copy of your Claim Form and all documentation submitted for your
records.6.
    
    You will not receive confirmation that your Claim Form has
been received unless
you send it via Certified Mail, Return Receipt Requested or by some other means that
provides you with proof of receipt.7.
    
    If you move, please send us your new address.
  
 YOU
MUST MAIL THIS CLAIM FORM AND YOUR SUPPORTING DOCUMENTATION BY   2006.
  
 D-7




---



##### 



EXHIBIT
E  
to Stipulation  
of Settlement


IN THE UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF TENNESSEE
GREENEVILLE DIVISION


IN RE: KING PHARMACEUTICALS,
    

    No. 2:03-CV-77INC. SECURITIES LITIGATIONDistrict Judge Thomas W. PhillipsTHIS DOCUMENT RELATES TO:All Actions
    
    Magistrate Judge Dennis H. Inman


[PROPOSED] FINAL JUDGMENT AND
ORDER OF DISMISSAL WITH PREJUDICE


The Wall Street Journal






---



##### 



E-2




---



##### 



E-3




---



##### 



res judicata
  E-4




---



##### 



THE HONORABLE THOMAS W. PHILLIPS
UNITED STATES
DISTRICT JUDGE
 E-5